Labiotech.eu

News and Trends 15 Jun 2017

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug. At the 2017 Annual European Congress of Rheumatology, currently being held in Madrid, Novartis has presented new data showing that Cosentyx (secukinumab) keeps improving symptoms of ankylosing spondylitis after three years of treatment and […]

June 15, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 15 Jun 2017

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […]

June 15, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 15 Jun 2017

MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences

LifeArc will draw funds from royalties of MSD’s successful checkpoint inhibitor Keytruda to invest in life sciences in both academic and business sectors. Born from the UK’s Medical Research Council, MRC Technology is a charity focused on supporting medical scientific research. Today, it becomes LifeArc and starts an ambitious new plan to invest up to […]

June 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Jun 2017

Where to Find the Perfect Mix of International and German Biotechs? Berlin!

Germany’s capital city Berlin is the perfect meeting place for international and German biotech companies. See here why the city has become a hotspot for life sciences research institutions and businesses! “Berlin! Berlin! We’re going to Berlin!” It might be a phrase usually sung by football fans, but maybe it’s time to have it chanted by other […]

June 15, 2017 - 6 minutesmins - By External Contributor

Expert Advice 15 Jun 2017

6 Ways to get Traction as a Biotech Startup

In 1989, Joshua Boger, founder of Vertex Pharmaceuticals, was on a mission to launch a new generation of biotech companies, but he didn’t have much to show. Fortunately, he understood rapidly that a biotech company needs a solid story in order to succeed. In biotech, “your story is your product”: people need to be enthusiastic […]

June 15, 2017 - 6 minutesmins - By Philip Hemme

News and Trends 14 Jun 2017

Understand your Biologics: De-Risking the Biotech Pipeline

Characterizing biologics has become an essential step for successful drug development. We connected with SCIEX to learn how to tackle the biggest challenges. Biologics are taking over the market. Some of the top-selling drugs worldwide are antibodies and recombinant proteins, and new technologies such as Antibody-Drug Conjugates (ADCs) are on track to revolutionize the extremely […]

June 14, 2017 - 5 minutesmins - By External Contributor

News and Trends 14 Jun 2017

Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer

The RAIDs consortium made its closing event last week. After 4.5 years of studies, it has managed to change our appreciation of HPV cervical cancer towards building intelligent targeted therapy designs. Every year in Europe, 16,000 women die from cervical cancer and another 34,000 are newly diagnosed, which makes it the second most frequent form […]

June 14, 2017 - 5 minutesmins - By Timothé Cynober

News and Trends 14 Jun 2017

French Hepatitis Cure is on Track with Positive Phase I Results

Enyo Pharma has announced that its lead candidate EYP001, indicated for the treatment of hepatitis B, successfully cleared a Phase Ia trial. Enyo Pharma is one of the hottest biotechs in Lyon that is developing new treatments against viruses, including hepatitis B or severe influenza infections. Its key asset, EYP001, is a farnesoid X receptor (FXR) agonist indicated […]

June 14, 2017 - 3 minutesmins - By Melanie De Almeida

Centogene Rare Disease Diagnostics Series A

News and Trends 13 Jun 2017

German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases

Centogene has raised €25M in a Series A round to support the global expansion of its genome analysis platform, which is specialized in rare diseases. The German biotech Centogene is pioneering the development of genetic diagnostic tests to address the challenges of personalized medicine in order to match therapies more effectively to patients. Founded in 2005, the […]

June 13, 2017 - 2 minutesmins - By Melanie De Almeida

In Depth 13 Jun 2017

Will Gene Editing Bypass the GMO Struggle or Worsen Public Distrust?

In the US, the first CRISPR-edited crops were able to bypass GMO regulations, but Europe’s plant scientists are still awaiting the final go ahead. In April 2016, the US Department of Agriculture (USDA) gave the green light to the first CRISPR-edited crops, a mushroom that has been engineered to resist browning and a waxy corn from […]

June 13, 2017 - 6 minutesmins - By Melanie De Almeida

News and Trends 12 Jun 2017

BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies

BioNTech has reported a new technology that could overcome some of the most challenging issues of antibody production by encoding them into mRNA drugs. BioNTech, one of the most advanced companies in the mRNA therapeutics field, has reported preclinical data for a new class of mRNA drugs that instruct the body to create its own […]

June 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jun 2017

Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies

Targovax has raised €21M (NOK200M) in a private placement, which the biotech will use to fund data read-outs from clinical trials and CMC development. Targovax, based in Oslo, is developing a number of immunotherapies for treatment-resistant tumors. The biotech’s pipeline is based on its two platforms, ONCOS, an oncolytic virus, which is being developed to treat melanoma, […]

June 12, 2017 - 2 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences

Where to Find the Perfect Mix of International and German Biotechs? Berlin!

6 Ways to get Traction as a Biotech Startup

Understand your Biologics: De-Risking the Biotech Pipeline

Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer

French Hepatitis Cure is on Track with Positive Phase I Results

German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases

Will Gene Editing Bypass the GMO Struggle or Worsen Public Distrust?

BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies

Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!